Mersana Therapeutics Inc (MRSN) Options

Guess
.45 is the bottom 🤔

MRSN..........................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783

Conference call tomorrow

https://finance.yahoo.com/news/mersana-therapeutics-provides-business-announces-120100840.html

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-ne...

https://x.com/MersanaADC/status/1894402567268176148?t=QScofmUgyO7wUuukSylYWw&s=19

Guess .50 is bottom

I Anticipate a good week here

MRSN................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783

🚀💰️

MRSN VOLUME TO DOLLA

MRSN GAPPA

MRSN.................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783

MRSN MINI BIO GETTING VOLUME

MRSN.................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783

MRSN, under $2

MRSN.............................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783

MRSN....................................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783

MRSN under $2

MRSN.............................https://stockcharts.com/h-sc/ui?s=MRSN&p=W&b=5&g=0&id=p86431144783

MRSN under $2

MRSN under $2

WLAN will explode within a year

MRSN note the cup and handle

Looking good still

Picking up some

Time for the push

Pump it up

Pre market pump incoming

MRSN new 52 week low

*some at 0.8

Grabbed some below 0.8 let’s see

Insider buying has happened yesterday. Form 4.

Nice! Good luck and happy trading!

Hey Miami, its already started to bounce.

MRSN Down 58% on clinical hold. Due to severity of report, not sure of any bounceability.

MRSN initiated at Citi with a $12 price target.


With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Vandana Singh
Fri, January 20, 2023 at 12:16 PM PST
In this article:

MRSN
+9.97%


Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12.

The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate.

Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the promising efficacy observed in Phase 1.

If the UPLIFT study results are positive, it will lead to a clear pathway to an accelerated approval filing by YE23.

The analyst writes that UpRi’s durability in Phase 1 was in-line or better than single-agent chemo SOC and the recently approved ADC Elahere.

On toxicity, reduced dosing and patient selection strategies should mitigate the risk of Gr4/5 pneumonitis seen earlier in Phase 1.

In December, Mersana announced its third significant collaboration agreement in 2022, reflecting its increasing role as an ADC partner.

The company announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA (OTC: MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets.

Mersana received an upfront payment of $30 million and is eligible to receive reimbursement of certain costs, up to $800 million in potential milestone payments.

Price Action: MRSN shares are up 10.48% at $6.43 on the last check Friday. (Up more in AH.)

Bladerunner

MRSN initiated at Citi with a $12 price target.


With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Vandana Singh
Fri, January 20, 2023 at 12:16 PM PST
In this article:

MRSN
+9.97%


Citi initiated coverage on Mersana Therapeutics Inc (NASDAQ: MRSN) with a Buy rating and a price target of $12.

The analyst says the topline registrational data (expected in mid-2023) from the UPLIFT Ph2 study evaluating upifitamab rilsodotin (UpRi; NaPi2b ADC) in platinum-resistant ovarian cancer (PROC) will be a catalyst of significant debate.

Citi analyst says that while readout will be binary, investors are underappreciating UPLIFT’s probability of success in NaPi2b-high patients, given the promising efficacy observed in Phase 1.

If the UPLIFT study results are positive, it will lead to a clear pathway to an accelerated approval filing by YE23.

The analyst writes that UpRi’s durability in Phase 1 was in-line or better than single-agent chemo SOC and the recently approved ADC Elahere.

On toxicity, reduced dosing and patient selection strategies should mitigate the risk of Gr4/5 pneumonitis seen earlier in Phase 1.

In December, Mersana announced its third significant collaboration agreement in 2022, reflecting its increasing role as an ADC partner.

The company announced a research collaboration and commercial license agreement with a subsidiary of Merck KGaA (OTC: MKKGY) to discover novel Immunosynthen ADCs directed against up to two targets.

Mersana received an upfront payment of $30 million and is eligible to receive reimbursement of certain costs, up to $800 million in potential milestone payments.

Price Action: MRSN shares are up 10.48% at $6.43 on the last check Friday. (Up more in AH.)

Bladerunner

Hey there! I am looking for a stock that will double in a year. Is $MRSN that stock??? Looks like it could. TIA.
MrDale.

Just bought in. $20.27

Panic sale for MRSN today...results are considered positive...

* * $MRSN Video Chart 09-14-2020 * *

Link to Video - click here to watch the technical chart video

* * $MRSN Video Chart 05-27-2020 * *

Link to Video - click here to watch the technical chart video

MRSN 44%% up,$15.20 going

AWESOME STOCK FOR SURE

fantastic gain today of 21% for all of us expected

MRSN bio beast here...did not take a big hit in the crash!!

MRSN blowing up something is up here!!

$MRSN GARBAGE Book Value Per Share only $1.73

expect to go higher here

* * $MRSN Video Chart 04-07-2020 * *

Link to Video - click here to watch the technical chart video

BUYOUT hmmmm